Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2008

Open Access 01-07-2008 | Gastrointestinal Oncology

A Place for Radiofrequency Ablation in the Treatment of Resectable Colorectal Liver Metastases?

Authors: V. E. de Meijer, MD, MSc, J. N. M. IJzermans, MD, PhD, C. Verhoef, MD

Published in: Annals of Surgical Oncology | Issue 7/2008

Login to get access

Excerpt

With great interest we read the exhaustive review “Radiofrequency Ablation versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?”1 in which Mulier et al. clearly summarizes the literature regarding radiofrequency ablation (RFA) as a treatment option for colorectal liver metastases (CRLM). The authors propose arguments and criteria for a noninferiority trial comparing RFA and resection for resectable CRLM with 5-year survival as a main outcome. However, we believe that they compare apples and oranges in their review of literature. In accordance with the Editorial by Curley,2 we do not think it is time for a randomized trial for resectable lesions yet. …
Literature
1.
Mulier S, Ni Y, Jamart J, et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial? Ann Surg Oncol 2008; 15:144–57.PubMedCrossRef
2.
Curley SA. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial? Ann Surg Oncol 2008; 15:11–3.PubMedCrossRef
3.
Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria. Radiology 2005; 235:728–39.PubMedCrossRef
4.
de Meijer VE, Verhoef C, Kuiper JW, et al. Radiofrequency ablation in patients with primary and secondary hepatic malignancies. J Gastrointest Surg 2006; 10:960–73.PubMedCrossRef
Metadata
Title
A Place for Radiofrequency Ablation in the Treatment of Resectable Colorectal Liver Metastases?
Authors
V. E. de Meijer, MD, MSc
J. N. M. IJzermans, MD, PhD
C. Verhoef, MD
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9843-z

Other articles of this Issue 7/2008

Annals of Surgical Oncology 7/2008 Go to the issue

Gastrointestinal Oncology

Radical Resection After IORT-Containing Multimodality Treatment is the Most Important Determinant for Outcome in Patients Treated for Locally Recurrent Rectal Cancer

Melanomas

A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma

Gastrointestinal Oncology

Squamous Cell Carcinoma of the Anal Canal: Utilization and Outcomes of Recommended Treatment in the United States

Hepatic and Pancreatic Tumors

Intraoperative Radiofrequency Ablation for Hepatocellular Carcinoma: Long-Term Results in a Large Series

Endocrine Tumors

Extent of Prophylactic Lymph Node Dissection in the Central Neck Area of the Patients with Papillary Thyroid Carcinoma: Comparison of Limited Versus Comprehensive Lymph Node Dissection in a 2-Year Safety Study

Medical Oncology

Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer